TY - JOUR
T1 - Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis
AU - Qin, J.
AU - Xie, Y.
AU - Wang, B.
AU - Hoshino, M.
AU - Wolff, D. W.
AU - Zhao, J.
AU - Scofield, M. A.
AU - Dowd, F. J.
AU - Lin, M. F.
AU - Tu, Y.
N1 - Funding Information:
This study was supported in part by Nebraska State Grant LB595, NIH 1R011CA125661 and by the Department of Defense Prostate Cancer Research Program W81XWH-07-1-0189 (YT). We thank Dr Laura Hansen for helpful comments and discussions; Dr Haihong Jiang, Lyudmila Batalkina, Dr Greg Perry and Lisa Linder-Stephenson for their technical assistance. The project described w as also supported by Grant G20RR024001 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official view s of the National Center for Research Resources or the National Institutes of Health.
PY - 2009/4/23
Y1 - 2009/4/23
N2 - Excessive activation of G-protein-coupled receptor (GPCR) and receptor tyrosine kinase (RTK) pathways has been linked to prostate cancer metastasis. Rac activation by guanine nucleotide exchange factors (GEFs) plays an important role in directional cell migration, a critical step of tumor metastasis cascades. We found that the upregulation of P-Rex1, a Rac-selective GEF synergistically activated by Gβγ freed during GPCR signaling, and PIP3, generated during either RTK or GPCR signaling, strongly correlates with metastatic phenotypes in both prostate cancer cell lines and human prostate cancer specimens. Silencing endogenous P-Rex1 in metastatic prostate cancer PC-3 cells selectively inhibited Rac activity and reduced cell migration and invasion in response to ligands of both epidermal growth factor receptor and G-protein-coupled CXC chemokine receptor 4. Conversely, expression of recombinant P-Rex1, but not its GEF-dead mutant, in non-metastatic prostate cancer cells, such as CWR22Rv1, increased cell migration and invasion through Rac-dependent lamellipodia formation. More importantly, using a mouse xenograft model, we showed that the expression of P-Rex1, but not its mutant, induced lymph node metastasis of CWR22Rv1 cells without an effect on primary tumor growth. Thus, by functioning as a coincidence detector of chemotactic signals from both GPCRs and RTKs, P-Rex1-dependent activation of Rac promotes prostate cancer metastasis.Oncogene (2009).
AB - Excessive activation of G-protein-coupled receptor (GPCR) and receptor tyrosine kinase (RTK) pathways has been linked to prostate cancer metastasis. Rac activation by guanine nucleotide exchange factors (GEFs) plays an important role in directional cell migration, a critical step of tumor metastasis cascades. We found that the upregulation of P-Rex1, a Rac-selective GEF synergistically activated by Gβγ freed during GPCR signaling, and PIP3, generated during either RTK or GPCR signaling, strongly correlates with metastatic phenotypes in both prostate cancer cell lines and human prostate cancer specimens. Silencing endogenous P-Rex1 in metastatic prostate cancer PC-3 cells selectively inhibited Rac activity and reduced cell migration and invasion in response to ligands of both epidermal growth factor receptor and G-protein-coupled CXC chemokine receptor 4. Conversely, expression of recombinant P-Rex1, but not its GEF-dead mutant, in non-metastatic prostate cancer cells, such as CWR22Rv1, increased cell migration and invasion through Rac-dependent lamellipodia formation. More importantly, using a mouse xenograft model, we showed that the expression of P-Rex1, but not its mutant, induced lymph node metastasis of CWR22Rv1 cells without an effect on primary tumor growth. Thus, by functioning as a coincidence detector of chemotactic signals from both GPCRs and RTKs, P-Rex1-dependent activation of Rac promotes prostate cancer metastasis.Oncogene (2009).
KW - G-protein-coupled receptors
KW - P-Rex1
KW - Prostate cancer metastasis
KW - Rac-selective guanine nucleotide exchange factor
KW - Receptor tyrosine kinases
UR - http://www.scopus.com/inward/record.url?scp=67349167687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349167687&partnerID=8YFLogxK
U2 - 10.1038/onc.2009.30
DO - 10.1038/onc.2009.30
M3 - Article
C2 - 19305425
AN - SCOPUS:67349167687
SN - 0950-9232
VL - 28
SP - 1853
EP - 1863
JO - Oncogene
JF - Oncogene
IS - 16
ER -